Артериальная гипертензия

Расширенный поиск

Новая страница в лечении артериальной гипертензии у больных сахарным диабетом. Первые данные исследования ADVANCE

Полный текст:


В статье приведены предпосылки к проведению, дизайн и первые результаты исследования ADVANCE, обсуж/ дается практическое значение полученных в этом исследовании результатов. Дан обзор состояния проблемы кон/ троля артериального давления у больных сахарным диабетом типа 2, подчеркнута важность исследования ADVANCE для понимания необходимости интенсивного снижения АД при сахарном диабете.

Об авторе

А. О. Конради
ФГУ ФЦСКИЭ им. В.А. Алмазова Росмедтехнологий

Список литературы

1. Guidelines Committee. 2003 European Society of Hypertension/ European Society of Cardiology guidelines for the management of arterial hypertension. J.Hypertension.2003; 21;1011-1053.


3. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure 2003.


5. Guidelines for the management of arterial hypertension. Eur Heart J 2007; 28:1462-1536.


7. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J, for the ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo/Scandinavian Cardiac Outcomes Trial/Blood Pressure Lowering Arm (ASCOT/BPLA): a multicentre randomised controlled trial. Lancet. 2005; 366: 895-906.


9. Mancia G, Ambrosioni E, Rosei EA, Leonetti G, Trimarco B, Volpe M; ForLife study group.Blood pressure control and risk of stroke in untreated and treated hypertensive patients screened from clinical practice: results of the ForLife study. J Hypertens. 2005;23(8):1575-1581.


11. Lewis EJ, Hunsisker LG, Clarke WR. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851-860.


13. Vinik AI, Ziegler D. Diabetic cardiovascular autonomic neuropathy. Circulation. 2007; 23;115(3):387-397.


15. Frattola A, Parati G, Castiglioni P, Paleari F, Ulian L, Rovaris G, Mauri G, Di Rienzo M, Mancia G.Lacidipine and blood pressure variability in diabetic hypertensive patients. Hypertension. 2000;:622-628.


17. Mancia G. Optimal control of blood pressure in patients with diabetes reduces the incidence of macro/ and microvascular events. J Hypertens Suppl. 2007 Jun;25 Suppl 1:S7-12.


19. Yudkin JS. Mechanisms of vascular disease in hypertension with special reference to diabetes. Semin Vasc Med. 2002;2(2):139-148.


21. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in Type 2 diabetes. UKPDS38. BMJ 1998; 317:703-713.


23. Schrier RW, Estacio RO, Esler A et al. Effects of aggressive blood pressure control in normotensive type 2 diabetes patients on albuminuria, retinopathy and strokes. Kidney Intern 2002; 61:1086-1097.


25. Estacio RO, effers BW, Gifford N et al. Effect of blood pressure conrol on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabets Care 2000; 23:B54-B64.


27. Opei L, Schall R. Old antihypertenisves and new diabetes. J Hypertension 2004; 22:1453-1458.


29. Messerli F, Grossman E, Leonetti G. Antihypertensive therapy and new onset diabetes. J Hypertens 2004; 22:1845-1847.


31. Yusuf S, Gerstein H, Hoogwert B et al. Ramipril and the development of diabetes. JAMA 2001; 286:1882-1885.


33. Kurtz TW, Pravenec M. Antidiabetic mechanisms of angiotensin/converting enzyme inhibitors and angiotensin receptor antagonists: beyond the renin/angiotensin system. J Hypertension 2004; :2253-2261.


35. Lindholm LH, Persson M, Alaupovic P et al. Metabolic outcome during 1 year in newly detected hypertensives: results of ALPINE study. J. Hypertens 2003; 21:1563-1547.


37. Brenner BM, Cooper ME, de Zeeuw D. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-869.


39. Savage PJ, Pressel SL, Curb JD. Influence of long/term, low/dose, diuretic/based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: The Systolic Hypertension in the Elderly Program. Arch Intern Med 1998; 158:741-751.


41. Voyaki SM, Staessen JA, Thijs L. Follow/up of renal function in treated and unteated older patients with isolated systolic hypertension. J Hypertens 2001 ; 19:511-519.


43. PROGESS Collaborative Study Group. Randomised trial period of perindopril/based blood pressure/lowering regimen among 6108 individuals with previous stroke or transient aschaemic attack. Lancet 2001 ; 358: 1033-1041.


45. Ruilope LM, Salveti A, Jamerson K. Renal function and intensive lowering of blood pressure in hypertensive participantsof the hypertension optimal treatment (HOT) study. J Am Soc Nephrol 2001 ; 12:218-225.


47. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICROHOPE substudy. Lancet 2000; 355:235-259.


49. Hansson L, Lindholm LH, Niskanen L et al. Effects of angiotensin/converting enzyme inhibitor compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP). Lancet 1999; 353:611-616.


51. Hansson L, Lindholm LH, Ekbom T ey al. Randomized trial of old and new antihypertensive drugs in elderly patients: cardiovascular morbidity and mortality in the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354:1751-1756.


53. Brown M., Palmer C., Castaigne L. et al. Morbidity and Mortality in Patients Randomized to Double/Blind Treatment with Long/Acting Calcium Channel Blockers or Diuretic in the International Nifedipine GITS Study: Intervention as a Goal in Hypertensive Treatment (INSIGHT). Lancet, 2000, 356, 366-372.


55. Hansson L, Hedner T, Lund/Johansen P et al. Randomized trial of effects of calcium antagonists compared with diuretics and beta/blockers on cardiovascular morbidity and mortality in hypertension (NORDIL). Study. Lancet 2000; 356:359-365.


57. Pepine CJ, Handberg EM, Cooper/DeHoff RM et al. A calcium antagonist versus a non/calcium antagonist hypertension treatment strategy fro the patients with CAD. The INVEST study. JAMA 2003; 290:2805-2816.


59. Lindholm LH, Ibsen T Dahlof B. Et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint Reduction in hypertension study (LIFE). Lancet 2002; 359;1004-1010.


61. Parving HH, Lehnert H, Brochner/Mortensen J et al., The effect of irbesartan on the development of diabetic nephropathy in patents with type 2 diabetes. N Eng J med 2001; 345:870-878. (IRMA)


63. Julius S, Kjeldsen SE, Weber M et al. Outcome in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomized trial. Lancet 2004; 363:2022-2031.


65. Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin/Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic. The Antihypertensive and Lipid/lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288; 2981-79.


67. Lewis EJ, Hunsicker LG, Bain RP et al. The effect of ACE inhibition on diabetic nephropathy. N Eng J Med 1993; 329:1456-1462.


69. Viberti GC, Mogenson CE, Groop LC et al. Effects of captopril on progression of clinical proteinuria in patients with insulin/dependent diabetes mellitus. JAMA 1994; 271:275-279.


71. Laffel LMB, McGill B, Gans DG et al. The beneficial effect of ACE with captopril on diabetic nephropathy in patients with type 1 diabetes mellitus. Am J ed 1995; 99:497-504.


73. Ravid M, Lang R, Rachmani R et al. Long/term renoprotective effect of ACE inhibition in non/insulin/dependent diabetes mellitus. Arch Intern Med 1996; 156:286-289.


75. Mogensen CE, Viberti G, Halmi S et al. Preterax in albumiuria progression (PREMIER) study group. Effect of low/dose perindopril/indapamide on albuminuria in diabetes. Hypertension 2003 ; 41 :1063-1071.


77. de Luca N, Mallion JM, O'Rourke MF, O'Brien E, Rahn KH, Trimarco B, Romero R, De Leeuw PW, Hitzenberger G, Battegay E, Duprez D, Sever P, Safar ME Regression of left ventricular mass in hypertensive patients treated with perindopril/ indapamide as a first/line combination: the REASON echocardiography study. Am J Hypertens. 2004;17(8):660-667.


79. Chalmes PA, Chapmen N, MacMahon S. Bllod pressure lowering in diabetes: a breief reviwer of the curent evidence and description of a new trial. Clin exp Physiol 2001; 28:1108-1111.


81. Rationale and design of the ADVANCE study: a randomized trial of blood pressure lowering and intensive glucose control in high/risk individuals with type 2 DM. cyion in Diebetes and Vascular Disease: PreterAx and DiamicroN Modified-release Controled Evaluation. ADVANCE collaborative group. J Hypertension Suppl 2001: 18:S21-S28.


Для цитирования:

Конради А.О. Новая страница в лечении артериальной гипертензии у больных сахарным диабетом. Первые данные исследования ADVANCE. Артериальная гипертензия. 2007;13(3):212-219.

For citation:

Konradi A.O. A new page in hypertension management in diabetes mellitus type 2. ADVANCE study first results. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2007;13(3):212-219. (In Russ.)

Просмотров: 239

Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.

ISSN 1607-419X (Print)
ISSN 2411-8524 (Online)